SREBF2 and astrocytoma (excluding glioblastoma): SREBP2 was expressed at higher levels in astrocytoma than in GBM (Fig. 1E, F, P < .001), meanwhile, astrocytoma had a significantly better overall survival than GBM (Fig. 1F, hazard ratio = 0.191, P < .0001).